ENXTPA:MSTY

Stock Analysis Report

Mainstay Medical International

Executive Summary

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia.

Snowflake

Fundamentals

Limited growth with weak fundamentals.

Share Price & News

How has Mainstay Medical International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.9%

MSTY

0.5%

FR Medical Equipment

-0.4%

FR Market


1 Year Return

-77.2%

MSTY

4.6%

FR Medical Equipment

9.5%

FR Market

Return vs Industry: MSTY underperformed the French Medical Equipment industry which returned 4.6% over the past year.

Return vs Market: MSTY underperformed the French Market which returned 9.5% over the past year.


Shareholder returns

MSTYIndustryMarket
7 Day2.9%0.5%-0.4%
30 Day7.1%3.6%0.06%
90 Dayn/a1.7%0.04%
1 Year-77.2%-77.2%5.5%4.6%13.3%9.5%
3 Year-77.8%-77.8%39.6%36.8%42.5%28.7%
5 Year-76.4%-76.4%128.1%119.3%71.0%45.0%

Price Volatility Vs. Market

How volatile is Mainstay Medical International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mainstay Medical International undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Mainstay Medical International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Mainstay Medical International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of MSTY’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Mainstay Medical International regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Mainstay Medical International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

88.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MSTY's forecast earnings growth is above the savings rate (0.7%).

Earnings vs Market: Insufficient data to determine if MSTY's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MSTY's revenue (88.7% per year) is forecast to grow faster than the French market (4.4% per year).

High Growth Revenue: MSTY's revenue (88.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if MSTY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mainstay Medical International performed over the past 5 years?

19.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MSTY is unprofitable, but has reduced losses over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare MSTY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MSTY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.5%).


Return on Equity

High ROE: MSTY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: MSTY is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MSTY is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Mainstay Medical International's financial position?


Financial Position Analysis

Short Term Liabilities: MSTY has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MSTY has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MSTY has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MSTY's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: MSTY has a high level of physical assets or inventory.

Debt Coverage by Assets: MSTY has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MSTY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MSTY has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17.9% each year


Next Steps

Dividend

What is Mainstay Medical International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.6%markettop25%4.7%industryaverage1.4%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MSTY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MSTY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MSTY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MSTY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MSTY's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

What is the CEO of Mainstay Medical International's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Jason Hannon (47yo)

2yrs

Tenure

US$596,641

Compensation

Mr. Jason Marshall Hannon, Esq., is Independent Non-Executive Director at Sequana Medical NV since May 23, 2019. He serves as Director of Kuros Biosciences AG since June 14, 2018. He has been the Chief Exe ...


CEO Compensation Analysis

Compensation vs. Market: Jason has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the French market.

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.5yrs

Average Tenure

47.5yo

Average Age

Experienced Management: MSTY's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

4.3yrs

Average Tenure

53.5yo

Average Age

Experienced Board: MSTY's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jason Hannon (47yo)

    CEO & Director

    • Tenure: 2yrs
    • Compensation: US$596.64k
  • Matt Onaitis (48yo)

    CFO & Company Secretary

    • Tenure: 1.2yrs
  • Jan Heemels (56yo)

    Vice President of Marketing

    • Tenure: 1.8yrs
  • Prashant Rawat (45yo)

    Chief Operating Officer

    • Tenure: 0yrs
  • Wolfgang Frisch

    VP & MD of Germany

    • Tenure: 1.3yrs

Board Members

  • Antoine Papiernik-Berkhauer (53yo)

    Non-Executive Director

    • Tenure: 5.5yrs
  • Greg Garfield (56yo)

    Non-Executive Director

    • Tenure: 3.3yrs
  • Oern Stuge (65yo)

    Independent Non-Executive Chairman

    • Tenure: 0yrs
    • Compensation: US$106.29k
  • Jason Hannon (47yo)

    CEO & Director

    • Tenure: 2yrs
    • Compensation: US$596.64k
  • David Brabazon (49yo)

    Independent Non-Executive Director

    • Tenure: 5.5yrs
    • Compensation: US$61.42k
  • James Reinstein (54yo)

    Independent Non-Executive Director

    • Tenure: 4.3yrs
    • Compensation: US$61.42k
  • Dan Sachs (54yo)

    Non-Executive Director

    • Tenure: 5.5yrs
  • Nael Kassar (40yo)

    Non-Executive Director

    • Tenure: 3.3yrs

Company Information

Mainstay Medical International plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mainstay Medical International plc
  • Ticker: MSTY
  • Exchange: ENXTPA
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €31.578m
  • Shares outstanding: 8.77m
  • Website: https://www.mainstay-medical.com/en

Number of Employees


Location

  • Mainstay Medical International plc
  • 77 Sir John Rogerson’s Quay
  • Block C
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MSTY1ISE (Irish Stock Exchange)YesNew Ordinary SharesIEEURApr 2014
MSTYENXTPA (Euronext Paris)YesNew Ordinary SharesFREURApr 2014
MSTYPBATS-CHIXE (BATS 'Chi-X Europe')YesNew Ordinary SharesGBEURApr 2014
MMDZ.FOTCPK (Pink Sheets LLC)YesNew Ordinary SharesUSUSDApr 2014

Biography

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia. It develops ReActiv8, an implantable restorative neuros ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 21:19
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.